Reversible, extremely severe hypothyroidism in a patient with chronic hepatitis C treated with interferon-α

Thyroid

Volumn 6, Issue 3, 1996, Pages 249-252

  Sato, Kanji ^a   Miyakawa, Megumi ^a   Demura, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LEVOTHYROXINE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; FACE EDEMA; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MALAISE; PRIORITY JOURNAL; TREATMENT PLANNING;

FEMALE; HEPATITIS C; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; MIDDLE AGED; MYXEDEMA; THYROGLOBULIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0029739701     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Volpé R 1990 Immunology of human thyroid disease. In: Volpé R (ed) Autoimmune Diseases of the Endocrine System, CRC Press, Boston, pp 73-239.
2. Fried MW, Hoofnagel JH 1995 Therapy of hepatitis C. Semin Liver Dis 15:82-91.
3. Burman P, Tötterman HT, Öberg K, Karlsson FA 1986 Thyroid autoimmunity in patients on long-term therapy with leukocyte derived interferon. J Clin Endocrinol Metab 63:1086-1090.
4. Pichert G, Jost LM, Zöbeli L, Odermatt M, Pedio G, Stahel RA 1990 Thyroiditis after treatment with interleukin-2 and interferon α-2a. Br J Cancer 62:100-104.
5. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA 1991 Thyroid dysfunction associated with the chronic outpatient administration of recombinant interleukin-2. and recombinant interferon-alpha. J Immunother 10:448-455.
6. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH 1992 Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 102:2155-2160.
7. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesh W, Weissel M 1992 Thyroid autoimmunity and hypothyroidism during longterm treatment with recombinant interferon-alpha. Clin Exp Immunol 90:363-367.
8. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, Benhamou JP, Bok B 1993 Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol 39:657-661.
9. Watanabe U, Hashimoto E, Hasamitsu T, Obata H, Hayashi N 1994 The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol 89:399-403.
10. Pichert G, Jost LM, Zöbeli L, Odermart B, Pedio G, Stahel RA 1990 Thyroiditis after treatment with interleukin-2 and interferon α-2a. Br J Cancer 62:100-104.
11. Marcellin P, Pouteau M, Renard P, Grynblat JM, Linhart NC, Bok M, Benhamou JP 1992 Sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. Gut 33:855-856.
12. 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab 77:1439-1441.
13. Okamura K, Sato K, Ikenoue H, Yoshinari M, Nakagawa M, Kuroda T, Fujishima M 1988 Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. J Clin Endocrinol Metab 67:720-726.
14. Takasu N, Yamada T, Takasu M, Komiya I, Nagasawa Y, Aizawa T, Koizumi Y 1992 Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 326:513-518.
15. Matsuura N, Yamada Y, Nohara Y, Konishi J, Kasagi K, Endo K, Kojima H, Wataya K 1980 Familial neonatal hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. N Engl J Med 303:738-741.
16. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z 1982 Recom-binant leukocyte A Interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96:549-556.
17. 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-α, and interferon-γ in human thyrocytes in suspension culture. J Clin Endocrinol Metab 70:1735-1743.
18. Sato K, Yamazaki K, Shizume K, Yamakawa Y, Satoh T, Demura H, Kanaji Y, Jr, Obara T, Fujimoto Y, Aiba M, Kakiuchi T, Kanaji Y 1993 Pathogenesis of autoimmune hypothyroidism induced by lymphokine-activated killer (LAK) cell therapy: In vitro inhibition of human thyroid function by interleukin-2 in the presence of autologous intrathyroidal lymphocytes. Thyroid 3:179-188.
19. Daniels HM, Meager A, Feddelston ALW, Alexander GJM, Williams R 1990 Spontaneous production of tumor necrosis factor-α and interleukin-1β during interferon-α treatment of chronic HBV infection. Lancet 35:875-877.
20. Corssmit EPM, Heyligenberg R, Enden E, Sauerwein HP, Romjin JA 1995 Acute effects of interferon-α administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 80:3140-3144.